Jazz Ebt Per Ebit from 2010 to 2024

JAZZ Stock  USD 122.64  0.15  0.12%   
Jazz Pharmaceuticals Ebt Per Ebit yearly trend continues to be fairly stable with very little volatility. Ebt Per Ebit is likely to outpace its year average in 2024. During the period from 2010 to 2024, Jazz Pharmaceuticals Ebt Per Ebit regression line of annual values had r-squared of  0.41 and arithmetic mean of  0.62. View All Fundamentals
 
Ebt Per Ebit  
First Reported
2010-12-31
Previous Quarter
0.51493138
Current Value
0.66
Quarterly Volatility
0.57225116
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 303.9 M, Other Operating Expenses of 3.4 B or Operating Income of 607.5 M, as well as many indicators such as Price To Sales Ratio of 1.93, Dividend Yield of 0.0 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Ebt Per Ebit Growth Pattern

Below is the plot of the Ebt Per Ebit of Jazz Pharmaceuticals PLC over the last few years. It is Jazz Pharmaceuticals' Ebt Per Ebit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ebt Per Ebit10 Years Trend
Slightly volatile
   Ebt Per Ebit   
       Timeline  

Jazz Ebt Per Ebit Regression Statistics

Arithmetic Mean0.62
Geometric Mean0.78
Coefficient Of Variation92.43
Mean Deviation0.40
Median0.85
Standard Deviation0.57
Sample Variance0.33
Range2.0107
R-Value(0.64)
Mean Square Error0.21
R-Squared0.41
Significance0.01
Slope(0.08)
Total Sum of Squares4.58

Jazz Ebt Per Ebit History

2024 0.66
2023 0.51
2022 -0.73
2021 -0.66
2020 0.36
2019 0.85

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Ebt Per Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebt Per Ebit 0.51  0.66 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.